210 related articles for article (PubMed ID: 12885911)
21. Intranasal treatment with CpG-B oligodeoxynucleotides protects CBA mice from lethal equine herpesvirus 1 challenge by an innate immune response.
Kim SK; Shakya AK; O'Callaghan DJ
Antiviral Res; 2019 Sep; 169():104546. PubMed ID: 31247247
[TBL] [Abstract][Full Text] [Related]
22. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
Tengvall S; O'Hagan D; Harandi AM
Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
[TBL] [Abstract][Full Text] [Related]
23. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
[TBL] [Abstract][Full Text] [Related]
24. Mucosal delivery of CpG oligodeoxynucleotides expands functional dendritic cells and macrophages in the vagina.
Sajic D; Patrick AJ; Rosenthal KL
Immunology; 2005 Feb; 114(2):213-24. PubMed ID: 15667566
[TBL] [Abstract][Full Text] [Related]
25. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.
Morrison LA; Zhu L; Thebeau LG
J Virol; 2001 Feb; 75(3):1195-204. PubMed ID: 11152492
[TBL] [Abstract][Full Text] [Related]
26. OASL1 deficiency promotes antiviral protection against genital herpes simplex virus type 2 infection by enhancing type I interferon production.
Oh JE; Lee MS; Kim YJ; Lee HK
Sci Rep; 2016 Jan; 6():19089. PubMed ID: 26750802
[TBL] [Abstract][Full Text] [Related]
27. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge.
Morrison LA; Da Costa XJ; Knipe DM
Virology; 1998 Mar; 243(1):178-87. PubMed ID: 9527927
[TBL] [Abstract][Full Text] [Related]
28. In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa.
Linehan MM; Richman S; Krummenacher C; Eisenberg RJ; Cohen GH; Iwasaki A
J Virol; 2004 Mar; 78(5):2530-6. PubMed ID: 14963155
[TBL] [Abstract][Full Text] [Related]
29. Curcumin Can Decrease Tissue Inflammation and the Severity of HSV-2 Infection in the Female Reproductive Mucosa.
Vitali D; Bagri P; Wessels JM; Arora M; Ganugula R; Parikh A; Mandur T; Felker A; Garg S; Kumar MNVR; Kaushic C
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31947962
[TBL] [Abstract][Full Text] [Related]
30. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
31. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
Parr MB; Kepple L; McDermott MR; Drew MD; Bozzola JJ; Parr EL
Lab Invest; 1994 Mar; 70(3):369-80. PubMed ID: 8145530
[TBL] [Abstract][Full Text] [Related]
32. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
[TBL] [Abstract][Full Text] [Related]
33. A critical role for IL-15 in TLR-mediated innate antiviral immunity against genital HSV-2 infection.
Thatte A; DeWitte-Orr SJ; Lichty B; Mossman KL; Ashkar AA
Immunol Cell Biol; 2011 Aug; 89(6):663-9. PubMed ID: 21339766
[TBL] [Abstract][Full Text] [Related]
34. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2.
Milligan GN; Bernstein DI
Virology; 1995 Oct; 212(2):481-9. PubMed ID: 7571418
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
36. Adaptive immune responses fail to provide protection against genital HSV-2 infection in the absence of IL-15.
Gill N; Ashkar AA
Eur J Immunol; 2007 Sep; 37(9):2529-38. PubMed ID: 17668897
[TBL] [Abstract][Full Text] [Related]
37. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
McCluskie MJ; Weeratna RD; Davis HL
Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
[TBL] [Abstract][Full Text] [Related]
38. Mimicking herpes simplex virus 1 and herpes simplex virus 2 mucosal behavior in a well-characterized human genital organ culture.
Steukers L; Weyers S; Yang X; Vandekerckhove AP; Glorieux S; Cornelissen M; Van den Broeck W; Temmerman M; Nauwynck HJ
J Infect Dis; 2014 Jul; 210(2):209-13. PubMed ID: 24436451
[TBL] [Abstract][Full Text] [Related]
39. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
40. Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection.
Raghavan S; Nyström J; Fredriksson M; Holmgren J; Harandi AM
Infect Immun; 2003 Dec; 71(12):7014-22. PubMed ID: 14638791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
